Sumitomo Mitsui Trust Group’s Castle Biosciences CSTL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-443,882
Closed -$9.74M 1211
2022
Q2
$9.74M Buy
443,882
+15,699
+4% +$365K 0.01% 809
2022
Q1
$19.2M Sell
428,183
-105,494
-20% -$4.36M 0.01% 740
2021
Q4
$22.9M Buy
533,677
+5,755
+1% +$301K 0.01% 695
2021
Q3
$35.1M Buy
527,922
+82,810
+19% +$5.83M 0.02% 628
2021
Q2
$32.6M Buy
+445,112
New +$29.4M 0.02% 651

Other funds holding CSTL

Sumitomo Mitsui Trust Group's CSTL Position: Q3 2022 in Review

Sumitomo Mitsui Trust Group sold out of Castle Biosciences (CSTL) in Q3 2022, closing a stake of 443,882 shares — an estimated $9.74M sold.

Sumitomo Mitsui Trust Group first reported a position in CSTL in Q2 2021 and held it in 5 quarters. The position peaked at $35.1M in Q3 2021. 157 funds tracked by Wall St. Rank hold CSTL as of Q3 2022.

  • Sumitomo Mitsui Trust Group reported no remaining Castle Biosciences position as of Q3 2022 after selling out during the quarter.
  • Sumitomo Mitsui Trust Group sold 443,882 Castle Biosciences shares in Q3 2022, an estimated $9.74M.
  • Sumitomo Mitsui Trust Group first reported a position in Castle Biosciences in Q2 2021 and held it in 5 quarters.
  • Sumitomo Mitsui Trust Group's Castle Biosciences position peaked at $35.1M in Q3 2021.
  • 157 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2022.

Based on Sumitomo Mitsui Trust Group's 13F filing for Q3 2022, filed 21 Oct 2022.